Estrogen or antiprogestin treatment induces complete regression of pulmonary and axillary metastases in an experimental model of breast cancer progression

Carcinogenesis

Volumn 26, Issue 6, 2005, Pages 1055-1063

  Vanzulli, Silvia I ^b   Soldati, Rocío ^a   Meiss, Roberto ^b   Colombo, Lucas ^c   Molinolo, Alfredo A ^a,d   Lanari, Claudia ^a,e  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b ACADEMIA NACIONAL DE MEDICINA   (Argentina)

^c Instituto Angel Roffo   (Argentina)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^e INST DE BIOL Y MED EXPERIMENTAL   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGESTAGEN; ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P21; PROTEIN P27; CDKN1A PROTEIN, MOUSE; CDKN1B PROTEIN, MOUSE; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ESTRADIOL; GESTAGEN; MIFEPRISTONE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GROWTH; CANCER REGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; FEMALE; HISTOLOGY; LUNG METASTASIS; MITOSIS; MORPHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL NEOPLASM; LUNG TUMOR; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; PATHOLOGY; XENOGRAFT;

ANIMALS; APOPTOSIS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; ESTRADIOL; ESTROGENS; FEMALE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MIFEPRISTONE; MITOSIS; PROGESTINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRANSPLANTATION, HETEROLOGOUS; TUMOR SUPPRESSOR PROTEINS;

EID: 22344439300     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/bgi060     Document Type: Article

References (38)

1. National Cancer Institute (2004) Cancer Facts, Adjuvant Therapy for Breast Cancer: Questions and Answers.
2. Ward, H.W. (1973) Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br. Med. J., 1, 13-14.
3. Ingle, J.N., Ahmann, D.L., Green, S.J. et al. (1981) Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N. Engl. J. Med., 304, 16-21.
4. Santen, R.J., Lipton, A. and Kendall, J. (1974) Successful medical adrenalectomy with amino-glutethimide. Role of altered drug metabolism. JAMA, 230, 1661-1665.
5. Jordan, V.C. (1992) The strategic use of antiestrogens to control the development and growth of breast cancer. Cancer, 70, 977-982.
6. Carter, A.C., Sedransk, N., Kelley, R.M., Ansfield, F.J., Ravdin, R.G., Talley, R.W. and Potter, N.R. (1977) Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA, 237, 2079-2088.
7. Beex, L., Pieters, G., Smals, A., Koenders, A., Benraad, T. and Kloppenborg, P. (1981) Tamoxifen versus ethiny 1 estradiol in the treatment of postmenopausal women with advanced breast cancer. Cancer Treat. Rep., 65, 179-185.
8. Brunner, N., Spang-Thomsen, M. and Cullen, K. (1996) The T61 human breast cancer xenograft: an experimental model of estrogen therapy of breast cancer. Breast Cancer Res. Treat., 39, 87-92.
9. Jordan, V.C. (1994) Molecular mechanisms of antiestrogen action in breast cancer. Breast Cancer Res. Treat., 31, 41-52.
10. Kessel, D. (1986) Interactions among membrane transport systems: anthracyclines, calcium antagonists and anti-estrogens. Biochem. Pharmacol., 35, 2825-2826.
11. Sudo, K., Monsma, F.J., Jr and Katzenellenbogen, B.S. (1983) Antiestrogen-binding sites distinct from the estrogen receptor: subcellular localization, ligand specificity, and distribution in tissues of the rat. Endocrinology, 112, 425-434.
12. Arteaga, C.L., Koli, K.M., Dugger, T.C. and Clarke, R. (1999) Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-beta. J. Natl Cancer Inst., 91, 46-53.
13. Brunner, N., Spang-Thomsen, M., Vindelov, L. and Nielsen, A. (1983) Effect of 17 beta-oestradiol on growth curves and flow cytometric DNA distribution of two human breast carcinomas grown in nude mice. Br. J. Cancer, 47, 641-647.
14. Chisamore, M.J., Ahmed, Y., Bentrem, D.J., Jordan, V.C. and Tonetti, D.A. (2001) Novel antitumor effect of estradiol in athymic mice injected with a T47D breast cancer cell line overexpressing protein kinase Calpha. Clin. Cancer Res., 7, 3156-3165.
15. Schneider, M.R., Michna, H., Nishino, Y. and el Etreby, M.F. (1989) Antitumor activity of the progesterone antagonists ZK 98.299 and RU 38.486 in the hormone-dependent MXT mammary tumor model of the mouse and the DMBA- and the MNU-induced mammary tumor models of the rat. Eur. J. Cancer Clin. Oncol., 25, 691-701.
16. Schneider, M.R., Michna, H., Nishino, Y. and el Etreby, M.F. (1990) Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models. J. Steroid Biochem. Mol. Biol., 37, 783-787.
17. Women's Health Initiative (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288, 321-333.
18. Beral, V. and Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet, 362, 419-427.
19. Kordon, E., Lanari, C., Molinolo, A.A., Elizalde, P.V., Charreau, E.H. and Pasqualini, C.D. (1991) Estrogen inhibition of MPA-induced mouse mammary tumor transplants. Int. J. Cancer, 49, 900-905.
20. Montecchia, M.F., Lamb, C., Molinolo, A.A., Luthy, I.A., Pazos, P., Charreau, E., Vanzulli, S. and Lanari, C. (1999) Progesterone receptor involvement in independent tumor growth in MPA-induced murine mammary adenocarcinomas. J. Steroid Biochem. Mol. Biol., 68, 11-21.
21. Vanzulli, S., Efeyan, A., Benavides, F., Helguero, L., Peters, G., Shen, J., Conti, C.J., Lanari, C. and Molinolo, A. (2002) p21, p27 and p53 in estrogen and antiprogestin-induced tumor regression of experimental mouse mammary ductal carcinomas. Carcinogenesis, 23, 749-757.
22. Lamb, C.A., Helguero, L.A., Fabris, V., Lucas, C., Molinolo, A.A. and Lanari, C. (2003) Differential effects of raloxifene, tamoxifen and fulvestrant on amurine mammary carcinoma. Breast Cancer Res. Treat., 79, 25-35.
23. Molinolo, A.A., Lanari, C., Charreau, E.H., Sanjuan, N. and Pasqualini, C.D. (1987) Mouse mammary tumors induced by medroxyprogesterone acetate: immunohistochemistry and hormonal receptors. J. Natl. Cancer Inst., 79, 1341-1350.
24. Lanari, C., Kordon, E., Molinolo, A., Pasqualini, C.D. and Charreau, E.H. (1989) Mammary adenocarcinomas induced by medroxyprogesterone acetate: hormone dependence and EGF receptors of BALB/c in vivo sublines. Int. J. Cancer, 43, 845-850.
25. Montecchia, M.F., Molinolo, A. and Lanari, C. (1999) Reversal of estrogen-resistance in murine mammary adenocarcinomas. Breast Cancer Res. Treat., 54, 93-99.
26. Helguero, L.A., Viegas, M., Asaithamby, A., Shyamala, G., Lanari, C. and Molinolo, A.A. (2003) Progesterone receptor expression in medroxyprogesterone acetate-induced murine mammary carcinomas and response to endocrine treatment. Breast Cancer Res. Treat., 79, 379-390.
27. Gottardis, M.M., Jiang, S.Y., Jeng, M.H. and Jordan, V.C. (1989) Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res., 49, 4090-4093.
28. Jordan, V.C. (1976) Antiestrogenic and antitumor properties of tamoxifen in laboratory animals. Cancer Treat. Rep., 60, 1409-1419.
29. Wolf, D.M. and Jordan, V.C. (1994) Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res. Treat., 31, 117-127.
30. Gottardis, M.M. and Jordan, V.C. (1987) Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res., 47, 4020-4024.
31. Jordan, V.C. (1976) Effect of tamoxifen (ICI 46, 474) on initiation and growth of DMBA-induced rat mammary carcinomata. Eur. J. Cancer, 12, 419-424.
32. Institute of Laboratory Animal Resources, C.o.L.S.N.R.C. (1996) Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC.
33. Efeyan, A., Fabris, V., Merani, S., Lanari, C. and Molinolo, A.A. (2004) Establishment of two hormone-responsive mouse mammary carcinoma cell lines derived from a metastatic mammary tumor. Breast Cancer Res. Treat., 83, 233-244.
34. Lamb, C., Simian, M., Molinolo, A., Pazos, P. and Lanari, C. (1999) Regulation of cell growth of a progestin-dependent murine mammary carcinoma in vitro: progesterone receptor involvement in serum or growth factor-induced cell proliferation. J. Steroid Biochem. Mol. Biol., 70, 133-142.
35. Moody, S.E., Sarkisian, C.J., Hahn, K.T., Gunther, E.J., Pickup, S., Dugan, K.D., Innocent, N., Cardiff, R.D., Schnall, M.D. and Chodosh, L.A. (2002) Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell, 2, 451-461.
36. Gunther, E.J., Moody, S.E., Belka, G.K., Hahn, K.T., Innocent, N., Dugan, K.D., Cardiff, R.D. and Chodosh, L.A. (2003) Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev., 17, 488-501.
37. Connolly, E.M., Harmey, J.H., O'Grady, T., Foley, D., Roche-Nagle, G., Kay, E. and Bouchier-Hayes, D.J. (2002) Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. Br. J. Cancer, 87, 231-237.
38. Balana, M.E., Lupu, R., Labriola, L., Charreau, E.H. and Elizalde, P.V. (1999) Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas. Oncogene, 18, 6370-6379.